IBDEI1KA ; ; 19-NOV-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,26107,2)
 ;;=^5001937
 ;;^UTILITY(U,$J,358.3,26108,0)
 ;;=D06.9^^127^1271^69
 ;;^UTILITY(U,$J,358.3,26108,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,26108,1,3,0)
 ;;=3^Carcinoma in Situ of Cervix,Unspec
 ;;^UTILITY(U,$J,358.3,26108,1,4,0)
 ;;=4^D06.9
 ;;^UTILITY(U,$J,358.3,26108,2)
 ;;=^5001941
 ;;^UTILITY(U,$J,358.3,26109,0)
 ;;=D09.0^^127^1271^70
 ;;^UTILITY(U,$J,358.3,26109,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,26109,1,3,0)
 ;;=3^Carcinoma in Situ of Bladder
 ;;^UTILITY(U,$J,358.3,26109,1,4,0)
 ;;=4^D09.0
 ;;^UTILITY(U,$J,358.3,26109,2)
 ;;=^267742
 ;;^UTILITY(U,$J,358.3,26110,0)
 ;;=D45.^^127^1271^71
 ;;^UTILITY(U,$J,358.3,26110,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,26110,1,3,0)
 ;;=3^Polycythemia Vera
 ;;^UTILITY(U,$J,358.3,26110,1,4,0)
 ;;=4^D45.
 ;;^UTILITY(U,$J,358.3,26110,2)
 ;;=^96105
 ;;^UTILITY(U,$J,358.3,26111,0)
 ;;=D47.Z9^^127^1271^72
 ;;^UTILITY(U,$J,358.3,26111,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,26111,1,3,0)
 ;;=3^Neop of Uncertain Behavior of Lymphoid/Hematpoetc/Related Tissue
 ;;^UTILITY(U,$J,358.3,26111,1,4,0)
 ;;=4^D47.Z9
 ;;^UTILITY(U,$J,358.3,26111,2)
 ;;=^5002262
 ;;^UTILITY(U,$J,358.3,26112,0)
 ;;=C94.40^^127^1271^73
 ;;^UTILITY(U,$J,358.3,26112,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,26112,1,3,0)
 ;;=3^Acute Panmyelosis w/ Myelofibrosis,Not in Remission
 ;;^UTILITY(U,$J,358.3,26112,1,4,0)
 ;;=4^C94.40
 ;;^UTILITY(U,$J,358.3,26112,2)
 ;;=^5001843
 ;;^UTILITY(U,$J,358.3,26113,0)
 ;;=C94.41^^127^1271^74
 ;;^UTILITY(U,$J,358.3,26113,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,26113,1,3,0)
 ;;=3^Acute Panmyelosis w/ Myelofibrosis,In Remission
 ;;^UTILITY(U,$J,358.3,26113,1,4,0)
 ;;=4^C94.41
 ;;^UTILITY(U,$J,358.3,26113,2)
 ;;=^5001844
 ;;^UTILITY(U,$J,358.3,26114,0)
 ;;=C94.42^^127^1271^75
 ;;^UTILITY(U,$J,358.3,26114,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,26114,1,3,0)
 ;;=3^Acute Panmyelosis w/ Myelofibrosis,In Relapse
 ;;^UTILITY(U,$J,358.3,26114,1,4,0)
 ;;=4^C94.42
 ;;^UTILITY(U,$J,358.3,26114,2)
 ;;=^5001845
 ;;^UTILITY(U,$J,358.3,26115,0)
 ;;=D47.1^^127^1271^76
 ;;^UTILITY(U,$J,358.3,26115,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,26115,1,3,0)
 ;;=3^Chronic Myeloproliferative Disease
 ;;^UTILITY(U,$J,358.3,26115,1,4,0)
 ;;=4^D47.1
 ;;^UTILITY(U,$J,358.3,26115,2)
 ;;=^5002256
 ;;^UTILITY(U,$J,358.3,26116,0)
 ;;=D47.9^^127^1271^77
 ;;^UTILITY(U,$J,358.3,26116,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,26116,1,3,0)
 ;;=3^Neop of Uncertain Behavior of Lymphoid/Hematpoetc/Related Tissue,Unspec
 ;;^UTILITY(U,$J,358.3,26116,1,4,0)
 ;;=4^D47.9
 ;;^UTILITY(U,$J,358.3,26116,2)
 ;;=^5002260
 ;;^UTILITY(U,$J,358.3,26117,0)
 ;;=D47.Z9^^127^1271^78
 ;;^UTILITY(U,$J,358.3,26117,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,26117,1,3,0)
 ;;=3^Neop of Uncertain Behavior of Lymphoid/Hematpoetc/Related Tissue,NEC
 ;;^UTILITY(U,$J,358.3,26117,1,4,0)
 ;;=4^D47.Z9
 ;;^UTILITY(U,$J,358.3,26117,2)
 ;;=^5002262
 ;;^UTILITY(U,$J,358.3,26118,0)
 ;;=A15.0^^127^1272^103
 ;;^UTILITY(U,$J,358.3,26118,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,26118,1,3,0)
 ;;=3^Tuberculosis of Lung
 ;;^UTILITY(U,$J,358.3,26118,1,4,0)
 ;;=4^A15.0
 ;;^UTILITY(U,$J,358.3,26118,2)
 ;;=^5000062
 ;;^UTILITY(U,$J,358.3,26119,0)
 ;;=A31.0^^127^1272^87
 ;;^UTILITY(U,$J,358.3,26119,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,26119,1,3,0)
 ;;=3^Pulmonary Mycobacterial Infection
 ;;^UTILITY(U,$J,358.3,26119,1,4,0)
 ;;=4^A31.0
 ;;^UTILITY(U,$J,358.3,26119,2)
 ;;=^5000149
 ;;^UTILITY(U,$J,358.3,26120,0)
 ;;=B95.5^^127^1272^93
 ;;^UTILITY(U,$J,358.3,26120,1,0)
 ;;=^358.31IA^4^2
